CD86 and neoplasm: The results show that combination therapy increase in local tumor infiltration with more mature CD86+ DCs, activated IFN-γ+CD8+ T cells and tumor antigen-specific T cells (gp70-tetramer+ CD8+ T cells) compared to the OVV or mNbTIM3 treated mice (Fig. 2A).